Kalytera Therapeutics, Inc.

CVE: KLY


Canadian symbol: KLY.V
US symbol: KALTF

Currency in CAD

Valuation Measures

Market Cap (intraday) 512.89M
Enterprise Value 316.04M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.78
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 2.95
52-Week Change 3-25.00%
S&P500 52-Week Change 35.66%
52 Week High 30.0600
52 Week Low 30.0100
50-Day Moving Average 30.0303
200-Day Moving Average 30.0310

Share Statistics

Avg Vol (3 month) 31.36M
Avg Vol (10 day) 3N/A
Shares Outstanding 5515.46M
Float 512.35M
% Held by Insiders 10.13%
% Held by Institutions 14.76%
Shares Short (Jun. 29, 2020) 4108.28k
Short Ratio (Jun. 29, 2020) 40.11
Short % of Float (Jun. 29, 2020) 4N/A
Short % of Shares Outstanding (Jun. 29, 2020) 40.02%
Shares Short (prior month May 28, 2020) 4618.72k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:2
Last Split Date 3Jan. 10, 2017

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec. 30, 2018
Most Recent Quarter (mrq)Sep. 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-17.16%
Return on Equity (ttm)-191.78%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-11.55M
Diluted EPS (ttm)-0.0410
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)31k
Total Cash Per Share (mrq)0
Total Debt (mrq)3.18M
Total Debt/Equity (mrq)67.29
Current Ratio (mrq)0.14
Book Value Per Share (mrq)0.01

Cash Flow Statement

Operating Cash Flow (ttm)-7.15M
Levered Free Cash Flow (ttm)-1.8M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
KLY.V
Kalytera Therapeutics
3 months ago
KLY.V
Kalytera Therapeutics
4 months ago
KLY.V
Kalytera Therapeutics
4 months ago
KLY.V
Kalytera Therapeutics
7 months ago
KLY.V
Kalytera Therapeutics
7 months ago
KLY.V
Kalytera Therapeutics
8 months ago
KLY.V
Kalytera Therapeutics
8 months ago
KLY.V
Kalytera Therapeutics
8 months ago
KLY.V
Kalytera Therapeutics
10 months ago
KLY.V
Kalytera Therapeutics
10 months ago
KLY.V
Kalytera Therapeutics
10 months ago
KLY.V
Kalytera Therapeutics
10 months ago
KLY.V
Kalytera Therapeutics
10 months ago
KLY.V
Kalytera Therapeutics
11 months ago
KLY.V
Kalytera Therapeutics
11 months ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago
KLY.V
Kalytera Therapeutics
1 year ago

Currency in CAD
Earnings EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/AN/AN/AN/A
Revenue EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings HistoryInvalid DateInvalid DateInvalid DateInvalid Date
EPS Est.N/AN/AN/AN/A
EPS ActualN/AN/AN/AN/A
DifferenceN/AN/AN/AN/A
Surprise %N/AN/AN/AN/A
EPS TrendCurrent Qtr.Next Qtr.Current YearNext Year
Current Estimate0000
7 Days Ago0000
30 Days Ago0000
60 Days Ago0000
90 Days Ago0000
EPS RevisionsCurrent Qtr.Next Qtr.Current YearNext Year
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesKLY.VIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
0.13%% of Shares Held by All Insider
4.76%% of Shares Held by Institutions
4.76%% of Float Held by Institutions
1Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Kalytera Therapeutics, Inc.


Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company's Private Placement

Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company’s Private Placement

SAN FRANCISCO, June 30, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided updates regarding the following three matters: (1) the delay in filing of its annual financial statements for the year ending December 31, 2019 and the accompanying Management’s Discussion and Analysis... Read More...
Kalytera Provides Update Regarding Acquisition of Salzman Group

Kalytera Provides Update Regarding Acquisition of Salzman Group

SAN FRANCISCO, June 16, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that it is working with Salzman Group toward completing definitive agreements for Kalytera’s acquisition of Salzman Group (the “Acquisition”). On May 19, 2020, Kalytera announced that it had signed a ... Read More...
Kalytera Announces Data Demonstrating that R-107 Prevents Tissue Damage and Increases Survival in a Murine Study of Chlorine Inhalational Lung Injury

Kalytera Announces Data Demonstrating that R-107 Prevents Tissue Damage and Increases Survival in a Murine Study of Chlorine Inhalational Lung Injury

SAN FRANCISCO, June 15, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced proof-of-concept data demonstrating that R-107 reduces tissue damage and increases survival in a lethal rodent model of chlorine inhalational lung injury (“CILI”) that mimics the pulmonary damage of c... Read More...
Kalytera Announces Data from Study in Rats Demonstrating Proof of Concept for R-107 in COVID-19 Associated PAH

Kalytera Announces Data from Study in Rats Demonstrating Proof of Concept for R-107 in COVID-19 Associated PAH

SAN FRANCISCO, June 09, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data for R-107, its liquid nitric oxide donor, in treatment of pulmonary arterial hypertension (“PAH”) in the setting of acute respiratory distress syndrome (“ARDS”). These result... Read More...
Kalytera Provides Data Demonstrating that Prodrug R-107 Provides Sustained Release of Nitric Oxide  

Kalytera Provides Data Demonstrating that Prodrug R-107 Provides Sustained Release of Nitric Oxide  

SAN FRANCISCO, June 05, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new in vivo data demonstrating that R-107 exhibits rapid conversion to its active payload R-100 in rats, followed by sustained release of nitric oxide from R-100.Kalytera announced on May 19, 2020 tha... Read More...
Kalytera Announces Filing of Provisional Patent Protecting Use of R-107 for Treatment of Coronavirus and COVID-19 Associated Pneumonia

Kalytera Announces Filing of Provisional Patent Protecting Use of R-107 for Treatment of Coronavirus and COVID-19 Associated Pneumonia

SAN FRANCISCO, June 02, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that Salzman Group, Inc. has filed a provisional patent application protecting the use of its proprietary, liquid, nitric oxide donor, R-107, for therapy of coronavirus and COVID-19 associated pneumon... Read More...
Kalytera Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease

Kalytera Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease

SAN FRANCISCO, May 29, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data demonstrating that R-107 reduces tissue damage and preserves organ function in a lethal rodent model of sepsis that resembles the circulatory shock seen with COVID-19 associat... Read More...
Kalytera Announces Binding Agreement to Acquire Salzman Group

Kalytera Announces Binding Agreement to Acquire Salzman Group

SAN FRANCISCO, May 19, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it has signed a binding Letter of Intent dated May 12, 2020 (the “LOI”) to acquire Salzman Group, Inc., a privately held company located in West Tisbury, MA (“Salzman Group”). Salzman Group is t... Read More...
Kalytera and Stero Biotechs Will Not Proceed with Acquisition

Kalytera and Stero Biotechs Will Not Proceed with Acquisition

SAN FRANCISCO, April 13, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that it will not proceed with the previously announced acquisition of Stero Biotechs, Ltd. (“Stero”), and that Stero and Kalytera have terminated the Letter of Intent relating to the acquisition.“Alt... Read More...
Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition

Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition

SAN FRANCISCO and TEL AVIV, Israel, March 18, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided additional details regarding the terms of its planned acquisition of Stero Biotechs, Ltd. (“Stero”). Stero is a privately held Israeli company that is developing cannabidiol (“C... Read More...
Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement

Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement

SAN FRANCISCO, Calif. and TEL AVIV, Israel, Feb. 19, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a modification to the sale period contemplated by the irrevocable selling agreement between Salzman Group and its broker with respect to common shares of Kalytera.  The ... Read More...
Kalytera Announces New Payments Agreement with the Salzman Group of Israel

Kalytera Announces New Payments Agreement with the Salzman Group of Israel

SAN FRANCISCO and TEL AVIV, Israel, Feb. 07, 2020 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has entered into a new agreement reached with the Salzman Group of Israel (the “Agreement”), under which Kalytera will pay the Salzman Group USD$300,000 through issuance... Read More...
Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019

Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019

SAN FRANCISCO and TEL AVIV, Israel, Dec. 20, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has not paid the principal (in the amount of C$453,000) and interest (in the amount of C$19,323.96) owing on its 9% secured convertible debentures due December 20, 2019 ... Read More...
Curaleaf Executive Chairman Boris Jordan Named to Bloomberg Businessweek's 2019 Bloomberg 50 List

Curaleaf Executive Chairman Boris Jordan Named to Bloomberg Businessweek's 2019 Bloomberg 50 List

The annual list includes innovators, entrepreneurs, and leaders who have changed the global business landscape in measurable ways over the past yearWAKEFIELD, Mass., Dec. 4, 2019 -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading vertically integrated cannabis operator in the United States, is proud to announce ... Read More...
Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD

Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD

SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that research reported in two peer-reviewed articles published in Blood provide further evidence supporting the activity of cannabidiol (“CBD”) in prevention and treatment of ac... Read More...
Kalytera Provides Update on Private Placement of Common Shares and Common Share Purchase Warrants

Kalytera Provides Update on Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO and TEL AVIV, Israel, Oct. 21, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce that it has closed an additional tranche of its private placement, for 1,974,445 common shares of the Company and 1,974,445 common share purchase warrants for aggregate g... Read More...
Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease

Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease

SAN FRANCISCO and TEL AVIV, Israel, Oct. 02, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce that the European Patent Office has issued a Notice of Allowance for EU Patent Application Number 14791611.8 covering the use of cannabidiol (“CBD”) in the treatment of g... Read More...
Kalytera Announces Closing of First Tranche of Private Placement of Common Shares and Common Share Purchase Warrants

Kalytera Announces Closing of First Tranche of Private Placement of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO and TEL AVIV, Israel, Sept. 16, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of the first tranche of its private placement, for 10,946,423 common shares of the Company and 10,946,423 common share purchase warrants for aggregate gross... Read More...
Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants

Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants

SAN FRANCISCO and TEL AVIV, Israel, Aug. 21, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it intends to raise up to approximately CDN $1.5 million (USD $1.13 million) in a private placement (the “Private Placement”) of common shares and common share purchase war... Read More...
Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study

Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study

Significantly Positive Phase 2 Results Eliminate Need for High Dose CohortSAN FRANCISCO and TEL AVIV, Israel, Aug. 19, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that interim results from the Company’s Phase 2 clinical study evaluating cannabidiol (“CBD”) for the p... Read More...
Kalytera Will Not Proceed with Vote on Potential Share Consolidation

Kalytera Will Not Proceed with Vote on Potential Share Consolidation

SAN FRANCISCO and TEL AVIV, Israel, July 26, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “Company” or “Kalytera”) announced today that after consultations with major shareholders, the board of directors of the Company has decided not to proceed at this time with the shareholder vote with respect to the aut... Read More...
Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

SAN FRANCISCO and TEL AVIV, Israel, June 18, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor.Ac... Read More...
Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office

Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office

SAN FRANCISCO and TEL AVIV, ISRAEL, May 29, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering Kalytera’s novel compositions of cannabidiol (“... Read More...
Kalytera Announces Data Further Elucidating CBD's Mechanisms of Action in Prevention of GVHD

Kalytera Announces Data Further Elucidating CBD’s Mechanisms of Action in Prevention of GVHD

New Research Demonstrates Activity of CBD in Repair of Damaged Epithelial CellsSAN FRANCISCO and TEL AVIV, Israel, May 28, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced new laboratory findings demonstrating that cannabidiol (“CBD”) acts through a distinct biological p... Read More...
Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

SAN FRANCISCO and TEL AVIV, Israel, May 21, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has engaged Echelon Wealth Partners to determine the value, on a risk-adjusted basis, of its cannabidiol ("CBD") therapeutic products for the prevention and treatment of graft versus host diseas... Read More...
Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering

Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.SAN FRANCISCO and TEL AVIV, Israel, May 14, 2019 -- Kalytera Therapeutics, Inc. (TSX Venture: KLY) (KALTF) (the “Company” or “Kalytera”) is pleased to anno... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
KLY.V
TSX Venture Exchange (former Canadian Ventures Exchange)
TSX Venture Exchange (former Canadian Ventures Exchange)0.03CAD--
S6V4.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.01EUR--
KLY.CCP
Canadian Composite Quote/Trade
Canadian Composite Quote/Trade0.03CAD0.00%
S6V4.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.01EUR-11.84%
S6V4.BE
Berlin Stock Exchange
Berlin Stock Exchange0.02EUR0.00%
KALTF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.02USD--
KLY.GO
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities0.03CAD--
KALTF.PQ
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.01USD--
KLY.CXX
Nasdaq CX2
Nasdaq CX20.03CAD0.00%

Delayed data (1h)
NameAgePositionAppointed
Ronald P. Erickson
Interim Chairman of the Board
--Interim Chairman of the Board2017
Robert E. Farrell
President, Chief Executive Officer, Director
66President, Chief Executive Officer, Director2018
Victoria D. Rudman
Interim Chief Financial Officer, Treasurer, Secretary
50Interim Chief Financial Officer, Treasurer, Secretary2018
Sari Prutchi-Sagiv
Chief Scientific Officer
--Chief Scientific Officer2017
Moshe Yeshurun
Chief Medical Officer
--Chief Medical Officer2017
Michael Galloro
Director
--Director2014
Scott R. Cochlan
Independent Director
--Independent Director2012
Robin B. Hutchison
Independent Director
60Independent Director2019
Douglas G. Manner
Independent Director
56Independent Director2012
Steven R. VanSickle
Independent Director
--Independent Director2012


Share this page